Unknown

Dataset Information

0

Rituximab does not reset defective early B cell tolerance checkpoints.


ABSTRACT: Type 1 diabetes (T1D) patients show abnormalities in early B cell tolerance checkpoints, resulting in the accumulation of large numbers of autoreactive B cells in their blood. Treatment with rituximab, an anti-CD20 mAb that depletes B cells, has been shown to preserve ? cell function in T1D patients and improve other autoimmune diseases, including rheumatoid arthritis and multiple sclerosis. However, it remains largely unknown how anti-B cell therapy thwarts autoimmunity in these pathologies. Here, we analyzed the reactivity of Abs expressed by single, mature naive B cells from 4 patients with T1D before and 52 weeks after treatment to determine whether rituximab resets early B cell tolerance checkpoints. We found that anti-B cell therapy did not alter the frequencies of autoreactive and polyreactive B cells, which remained elevated in the blood of all patients after rituximab treatment. Moreover, the limited proliferative history of autoreactive B cells after treatment revealed that these clones were newly generated B cells and not self-reactive B cells that had escaped depletion and repopulated the periphery through homeostatic expansion. We conclude that anti-B cell therapy may provide a temporary dampening of autoimmune processes through B cell depletion. However, repletion with autoreactive B cells may explain the relapse that occurs in many autoimmune patients after anti-B cell therapy.

SUBMITTER: Chamberlain N 

PROVIDER: S-EPMC4701568 | biostudies-literature | 2016 Jan

REPOSITORIES: biostudies-literature

altmetric image

Publications

Rituximab does not reset defective early B cell tolerance checkpoints.

Chamberlain Nicolas N   Massad Christopher C   Oe Tyler T   Cantaert Tineke T   Herold Kevan C KC   Meffre Eric E  

The Journal of clinical investigation 20151207 1


Type 1 diabetes (T1D) patients show abnormalities in early B cell tolerance checkpoints, resulting in the accumulation of large numbers of autoreactive B cells in their blood. Treatment with rituximab, an anti-CD20 mAb that depletes B cells, has been shown to preserve β cell function in T1D patients and improve other autoimmune diseases, including rheumatoid arthritis and multiple sclerosis. However, it remains largely unknown how anti-B cell therapy thwarts autoimmunity in these pathologies. He  ...[more]

Similar Datasets

| S-EPMC6062007 | biostudies-literature
| S-EPMC3699182 | biostudies-literature
| S-EPMC5127630 | biostudies-literature
| S-EPMC4170028 | biostudies-literature
| S-EPMC4891998 | biostudies-literature
2015-03-10 | GSE66657 | GEO
| S-EPMC4830093 | biostudies-literature
| S-EPMC3366410 | biostudies-literature
| S-EPMC4275206 | biostudies-literature
| S-EPMC4550502 | biostudies-literature